Bragar Eagel & Squire, P.C. is Investigating American Renal Associates Holdings, Inc. (ARA) on Behalf of Stockholders and Encourages ARA Investors to Contact the Firm
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against American Renal Associates Holdings, Inc. (NYSE: ARA). Our investigation concerns whether American Renal has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On March 8, 2019, American Renal announced it would delay the filing of its earnings report for the fiscal year ended December 31, 2018, as it continues to examine reserve computations and other accounting practices that may have an impact on the company’s accounts receivable and revenue for fiscal year 2018, as well as fiscal years 2014 to 2017.
This news follows an October 2018 request by the Securities and Exchange Commission for documents concerning American Renal’s revenue recognition practices, collections, and other related matters.
On this news, American Renals’s share price fell by more than 16%, closing at $10.46 on March 8, 2019.
If you purchased or otherwise acquired American Renal shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into American Renal please go to https://bespc.com/ara/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.